This company is no longer active
Clarus Therapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
Key information
51.3%
Earnings growth rate
84.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 73.3% |
| Return on equity | n/a |
| Net Margin | -144.8% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Clarus Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 17 | -24 | 49 | 4 |
| 31 Mar 22 | 16 | -36 | 52 | 3 |
| 31 Dec 21 | 14 | -40 | 47 | 4 |
| 30 Sep 21 | 12 | -58 | 48 | 3 |
| 30 Jun 21 | 10 | -50 | 49 | 3 |
| 31 Mar 21 | 8 | -21 | 46 | 3 |
| 31 Dec 20 | 6 | -10 | 42 | 2 |
Quality Earnings: CRXT.Q is currently unprofitable.
Growing Profit Margin: CRXT.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CRXT.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CRXT.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRXT.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.7%).
Return on Equity
High ROE: CRXT.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.